Long-term outcomes of idiopathic inflammatory myopathies: a large-scale longitudinal cohort study
Authors:
- 6 May 2025
- journal article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 154, 103435
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82371810, 82372320, 82171788)
This publication has 45 references indexed in Scilit:
- Identification of Three Different Phenotypes in Anti–Melanoma Differentiation–Associated Gene 5 Antibody–Positive Dermatomyositis Patients: Implications for Prediction of Rapidly Progressive Interstitial Lung DiseaseArthritis & Rheumatology, 2023
- Long‐Term Outcomes and Prognosis Factors in Patients With Idiopathic Inflammatory Myopathies Based on Myositis‐Specific Autoantibodies: A Single Cohort StudyArthritis Care & Research, 2022
- Anti‐Jo1 autoantibodies, from clinic to the benchRheumatology & Autoimmunity, 2022
- Incidence, Prevalence, and Mortality of Dermatomyositis: A Population‐Based Cohort StudyArthritis Care & Research, 2021
- 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major SubgroupsArthritis & Rheumatology, 2017
- Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of SpainRheumatology International, 2017
- Anti–Melanoma Differentiation–Associated Protein 5–Associated Dermatomyositis: Expanding the Clinical SpectrumArthritis Care & Research, 2013
- Myopathy Associated With Antibodies to Signal Recognition ParticleArchives of Neurology, 2012
- International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathiesArthritis & Rheumatism, 2005
- Inclusion body myositis and myopathiesAnnals of Neurology, 1995